These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Molecular analysis of the BCR-ABL1 kinase domain in chronic-phase chronic myelogenous leukemia treated with tyrosine kinase inhibitors in practice: study by the Nagasaki CML Study Group.
    Author: Itonaga H, Tsushima H, Imanishi D, Hata T, Doi Y, Mori S, Sasaki D, Hasegawa H, Matsuo E, Nakashima J, Kato T, Horai M, Taguchi M, Matsuo M, Taniguchi H, Makiyama J, Sato S, Horio K, Ando K, Moriwaki Y, Sawayama Y, Ogawa D, Yamasaki R, Takasaki Y, Imaizumi Y, Taguchi J, Kawaguchi Y, Yoshida S, Joh T, Moriuchi Y, Nonaka H, Soda H, Fukushima T, Nagai K, Kamihira S, Tomonaga M, Yanagihara K, Miyazaki Y.
    Journal: Leuk Res; 2014 Jan; 38(1):76-83. PubMed ID: 24262285.
    Abstract:
    An appropriate trigger for BCR-ABL1 mutation analysis has not yet been established in unselected cohorts of chronic-phase chronic myelogenous leukemia patients. We examined 92 patients after 12 months of tyrosine kinase inhibitor (TKI) treatment in Nagasaki Prefecture, Japan. Univariate analysis revealed that significant factors associated with not attaining a major molecular response (MMR) were the presence of the minor BCR-ABL1 fusion gene, a low daily dose of TKI, and the emergence of BCR-ABL1 kinase domain mutations conferring resistance to imatinib. Factors associated with the loss of sustained MMR were a low daily dose of TKI and the emergence of alternatively spliced BCR-ABL1 mRNA with a 35-nucleotide insertion. Taken together, our results suggest that the search for BCR-ABL1 mutations should be initiated if patients have not achieved MMR following 12 months of TKI treatment.
    [Abstract] [Full Text] [Related] [New Search]